Pressmeddelande

BioStock: SynAct Pharma moves forward with filing process

Cision Publicerad: 04 Jul 08:58

Following previous studies in rheumatoid arthritis, SynAct Pharma knows much more about the possibilies and requirements for assessing resomelagon’s effect. The company is now acting on its strategy by initiating the filing process for a new clinical phase IIb study with resomelagon in patients with severe, newly diagnosed RA with signs of systemic inflammation. BioStock reached out to CEO Jeppe Øvlesen to learn more about the clinical trial, named ADVANCE.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/07/synact-pharma-moves-forward-with-filing-process/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nyheter om SynAct Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!